Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes

doi:10.1186/s12902-021-00690-0

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23362

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23362

Title:	Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes
Authors:	Yen, FS;Wei, JCC;Lin, MC;Hsu, CC;Hwu, CM
Keywords:	Insulin;Alpha-glucosidase inhibitors;All-cause mortality;Cardiovascular death;Coronary artery disease
Date:	2021
Issue Date:	2022-08-05T09:36:04Z (UTC)
Publisher:	BMC
Abstract:	BackgroundIn insulin-treated patients with type 2 diabetes mellitus (T2DM), glycemic control is usually suboptimal.MethodsThis study compared the risks of mortality and cardiovascular events in insulin-treated patients adding or not adding alpha-glucosidase inhibitors (AGIs).ResultsThis cohort study included data from the Taiwan National Health Insurance Research Database. In total, 17,417 patients newly diagnosed as having T2DM and undergoing insulin therapy during 2000-2012 were enrolled. Overall incidence rates of all-cause mortality, hospitalized coronary artery disease (CAD), stroke, and heart failure were compared between 4165 AGI users and 4165 matched nonusers. The incidence rates of all-cause mortality were 17.10 and 19.61 per 1000 person-years in AGI nonusers and users, respectively. Compared with nonusers, AGI users had a higher mortality risk [adjusted hazard ratio (aHR)=1.21, 95% confidence interval (CI)=1.05-1.40; p=0.01]. Regarding AGI use, aHRs (95% CI) for cardiovascular death, non-cardiovascular death, hospitalized CAD, stroke, and heart failure were 1.20 (0.83-1.74), 1.27 (1.07-1.50), 1.12 (0.95-1.31), 0.98 (0.85-1.14), and 1.03 (0.87-1.22) respectively.ConclusionAGI use was associated with higher risks of all-cause mortality and non-cardiovascular death in insulin-treated patients with T2DM. Therefore, adding AGIs in insulin-treated patients may not be appropriate.
URI:	http://dx.doi.org/10.1186/s12902-021-00690-0 https://www.webofscience.com/wos/woscc/full-record/WOS:000621051600001 https://ir.csmu.edu.tw:8080/handle/310902500/23362
Relation:	BMC ENDOCRINE DISORDERS ,2021,v21,issue 1
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	170	View/Open

Loading...